Tubeuf Sandy, Willis Thomas A, Potrata Barbara, Grant Hilary, Allsop Matthew J, Ahmed Mushtaq, Hewison Jenny, McKibbin Martin
Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
Yorkshire Regional Genetics Service, Chapel Allerton Hospital, Leeds, UK.
Eur J Hum Genet. 2015 Mar;23(3):285-91. doi: 10.1038/ejhg.2014.111. Epub 2014 Jun 11.
This paper investigates the willingness of adults with inherited retinal disease to undergo and pay for diagnostic genetic testing in three hypothetical scenarios and to explore the factors that influence decision making. Fifty patients were presented with three scenarios whereby genetic testing provided increasing information: confirming the diagnosis and inheritance pattern alone, providing additional information on future visual function, and identifying in addition a new treatment which could stabilise their condition. Willingness to pay (WTP) was elicited using an iterative bidding game. Regression analysis was used to investigate the probability of agreeing to and paying for testing. Qualitative data were also reviewed to provide a comprehensive understanding of WTP and decision making. The majority of participants agreed to undergo genetic testing in each of the three scenarios. Scenario 2 was the least acceptable with 78% of participants agreeing to genetic testing. The probability of agreeing to genetic testing decreased with age. Between 72 and 96% of participants reported a WTP for genetic testing. Average WTP was £539, £1516, and £6895 for scenarios 1, 2, and 3 respectively. Older participants and participants with higher incomes were willing to pay more for testing. Qualitative data provided additional detail about the rationale behind participants' decisions. The study suggests that patients with inherited retinal disease were willing to undergo and to pay for diagnostic genetic testing, suggesting that they valued the information it may provide. However, several patients preferred not to receive prognostic information and were less willing to pay for genetic testing that yielded such detail.
本文研究了患有遗传性视网膜疾病的成年人在三种假设情况下接受诊断性基因检测并为之付费的意愿,并探讨了影响决策的因素。向50名患者展示了三种情况,在这些情况下基因检测能提供越来越多的信息:仅确认诊断和遗传模式、提供关于未来视觉功能的额外信息,以及另外确定一种可稳定其病情的新治疗方法。使用迭代投标博弈来引出支付意愿(WTP)。采用回归分析来研究同意检测并为之付费的概率。还对定性数据进行了审查,以全面了解支付意愿和决策过程。大多数参与者同意在三种情况中的每一种情况下都接受基因检测。情况2是最不被接受的,78%的参与者同意进行基因检测。同意进行基因检测的概率随年龄增长而降低。72%至96%的参与者报告了对基因检测的支付意愿。情况1、2和3的平均支付意愿分别为539英镑、1516英镑和6895英镑。年龄较大的参与者和收入较高的参与者愿意为检测支付更多费用。定性数据提供了关于参与者决策背后理由的更多细节。该研究表明,患有遗传性视网膜疾病的患者愿意接受诊断性基因检测并为之付费,这表明他们重视检测可能提供的信息。然而,有几位患者更愿意不接受预后信息,并且不太愿意为产生此类详细信息的基因检测付费。